Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Clinical and Molecular Hepatology ; : 499-502, 2016.
Artigo em Inglês | WPRIM | ID: wpr-54507

RESUMO

Cirrhosis can occur with the development of portal vein thrombosis (PVT). PVT may aggravate portal hypertension, and it can lead to hepatic decompensation. The international guideline recommends for anticoagulation treatment to be maintained for at least 3 months in all patients with acute PVT. Low-molecular-weight-heparin and changing to warfarin is the usual anticoagulation treatment. However, warfarin therapy is problematic due to a narrow therapeutic window and the requirement for frequent dose adjustment, which has prompted the development of novel oral anticoagulants for overcoming these problems. We report a 63-year-old female who experienced complete resolution of recurrent acute PVT in liver cirrhosis after treatment with rivaroxaban.


Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Administração Oral , Inibidores do Fator Xa/uso terapêutico , Cirrose Hepática/complicações , Veia Porta , Recidiva , Rivaroxabana/uso terapêutico , Tomografia Computadorizada por Raios X , Trombose Venosa/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA